Literature DB >> 9856351

Circulating soluble CD5 in atopic dermatitis.

G W Noh1, K Y Lee.   

Abstract

The CD5/Leu-1 is involved in the activation of the T-cell helper function through T/B-cell collaboration by CD5/CD72 interaction. T-cell function is known to be dysregulated in atopic dermatitis. However, to date, the role of CD5 has not been investigated in atopic dermatitis, nor has the presence of circulating soluble CD5 been reported in atopic dermatitis. Five patients with atopic dermatitis who showed typical symptoms, 5 acute febrile patients and 5 normal subjects were tested. Peripheral blood mononuclear cells and plasma were separated. The T- and B-cells were separated using immunomagnetic beads. Reverse transcription polymerase chain reaction was performed using CD5 specific primers. Immunoblotting with the mouse antiCD5 monoclonal antibody was done. Circulating soluble CD5 was present only in 4 out of 5 atopic patients. However, it was not detected in acute febrile patients nor in normal subjects. CD5 mRNA expression was detected in all atopic patients and acute febrile patients. CD5 mRNA expression in T- and B-cells was tested in patients with atopic dermatitis and was detected only in the T-cells. In this study, circulating soluble CD5 was detected in atopic patients and soluble CD5 was suspected to participate in the pathogenesis of atopic dermatitis. CD5 mRNA expression was detected only in T-cells, which suggests that circulating soluble CD5 might be produced from T-cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856351

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  4 in total

Review 1.  The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease.

Authors:  Gloria Soldevila; Chander Raman; Francisco Lozano
Journal:  Curr Opin Immunol       Date:  2011-04-07       Impact factor: 7.486

Review 2.  Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents.

Authors:  María Velasco-de Andrés; Sergi Casadó-Llombart; Cristina Català; Alejandra Leyton-Pereira; Francisco Lozano; Fernando Aranda
Journal:  Cells       Date:  2020-12-03       Impact factor: 6.600

3.  Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts.

Authors:  Jose Manuel Sánchez-Maldonado; Rafael Cáliz; Miguel Ángel López-Nevot; Antonio José Cabrera-Serrano; Ana Moñiz-Díez; Helena Canhão; Rob Ter Horst; Luca Quartuccio; Signe B Sorensen; Bente Glintborg; Merete L Hetland; Ileana Filipescu; Eva Pérez-Pampin; Pablo Conesa-Zamora; Jerzy Swierkot; Alfons A den Broeder; Salvatore De Vita; Eva Rabing Brix Petersen; Yang Li; Miguel A Ferrer; Alejandro Escudero; Mihai G Netea; Marieke J H Coenen; Vibeke Andersen; João E Fonseca; Manuel Jurado; Katarzyna Bogunia-Kubik; Eduardo Collantes; Juan Sainz
Journal:  Front Immunol       Date:  2021-10-27       Impact factor: 7.561

4.  Evaluation of the frequency of CD5+ B cells as natural immunoglobulin M producers and circulating soluble CD5 in patients with bladder cancer.

Authors:  Zahra Roudafshani; Mir Hadi Jazayeri; Ahmad-Reza Mahmoudi; Reza Nedaeinia; Elahe Safari; Aboozar Jazayeri
Journal:  Mol Biol Rep       Date:  2019-10-05       Impact factor: 2.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.